3 results for "Lutathera".
Introduction: There are limited therapeutic options for patients with advanced midgut NETs progressing on first-line somatostatin analog therapy.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: MD Jonathan Strosberg
Introduction: Impairment in quality of life caused by tumor load and hormone-related symptoms is frequent in GEP-NET patients. In the Phase III NETTER-1 trial, patients with advanced, progressive midgut NETs were randomized to treatment with 177Lu-DOTATATE (177Lu; Lutathera®) or high-dose (60 mg) Octreotide LAR (Oct).
Conference: 14th Annual ENETS conference 2017 (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Prof. Jonathan Strosberg
Introduction: PRRT is a recognized salvage option for G1-G2 GEPNET. Currently, the Italian protocol (Lutathera AIFA Guidelines) consists in four fixed-dose of 177 Lu-DOTATATE. The dosimetry has recently been recognized as an important tool to guide PRRT but is not yet part of routine practice.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: MD Federica Scalorbi